1Laboratory of Hematology, Biology and Pathology Center, CHU Lille, Lille, France
2INSERM UMR-S 1172, Cancer Research Institute, Lille, France
3Department of Pediatric Hematology, IHOP, Hospices Civils de Lyon and Claude Bernard University, Lyon, France
4Laboratory of Hematology, Lyon-Sud Hospital, Hospices Civils de Lyon, Pierre Bénite, France
5INSERM U918, Centre Henri Becquerel, Institute for Research and Innovation in Biomedicine, Rouen, France.
Correspondence: Gauthier Decool (. e-mail: firstname.lastname@example.org).
Citation: Decool G, Domenech C, Grardel N, Plesa A, Raczkiewicz I, Ducourneau B, Ruminy P, Pages M-P, Girard S, Fenwarth L, Preudhomme C, Bertrand Y, Duployez N. Efficacy of Tyrosine Kinase Inhibitor Therapy in a Chemotherapy-refractory B-cell Precursor Acute Lymphoblastic Leukemia With ZC3HAV1-ABL2 Fusion. HemaSphere, 2019;0:0. http://dx.doi.org/10.1097/HS9.0000000000000193
Disclosure: The authors have indicated they have no potential conflicts of interest to disclose.
Authorship contributions: GD, ND, IR, BD, PR, LF, NG, and CP performed molecular analyses. AP performed flow cytometry. M-PP performed cytogenetic analyses. SG performed morphological diagnosis. CD and YB provided clinical data. GD, ND, CP, and YB wrote the manuscript which was approved by all coauthors.
This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0
Received February 1, 2019
Received in revised form February 20, 2019
Accepted February 21, 2019
Online date: March 5, 2019